Physicians' Academy for Cardiovascular Education

Atherosclerosis

Recently added learning

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

The mechanism of action of bempedoic acid

Feb. 2, 2020

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Harmful effects of alcohol and smoking on arterial system in adolescents

3' education - Sep. 4, 2018 - Marietta Charakida, MD - London, UK

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

Analogous to LDL-c, the lower the better also seems true for inflammation

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain

Imaging components of plaque not more informative than burden of plaque

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

5' education - Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

10' education - Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

3' education - Aug. 28, 2017

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

3' education - Aug. 27, 2017

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

3' education - Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

Bisphosphonate as a potential new treatment for CV risk reduction

10' education - Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)

Inflammation, the immune system and atherosclerosis

10' education - July 7, 2015 - Amsterdam IAS

Novel small molecule that inhibits PAI-1 in development to slow vascular aging

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Chicago, IL, USA

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Steps forward in lipid-lowering therapy

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA
##FULL_TITLE##

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

3' education - Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##FULL_TITLE##

ACCELERATE: No reduction of major CV events with CETP inhibition

3' education - Apr. 7, 2016 - ACC, Chicago 2016 - Stephen J. Nicholls, MD, PhD

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##FULL_TITLE##

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby
##FULL_TITLE##

CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Yanan Wang

Cardiovascular Inflammation and Immunity in Atherosclerosis:

10' education - June 7, 2015 - Amsterdam

Statin-loaded HDL nanoparticles

10' education - Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden

On demand 10" video

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

10' education - Aug. 28, 2017

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Bisphosphonate as a potential new treatment for CV risk reduction

10' education - Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)

Inflammation, the immune system and atherosclerosis

10' education - July 7, 2015 - Amsterdam IAS

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)
##FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker

Cardiovascular Inflammation and Immunity in Atherosclerosis:

10' education - June 7, 2015 - Amsterdam

Statin-loaded HDL nanoparticles

10' education - Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden

A marriage of clinical trial results and imaging findings with icosapent ethyl

Results of the EVAPORATE trial

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD
Three experts discuss detailed findings of the EVAPORATE study and how to interpret these. THe EVAPORATE trial examined the effect of icosapent ethyl on plaque formation and was a mechanistic study for the REDUCE-IT trial.

Three experts discuss the findings of the EVAPORATE study in detail and how to interpret these. The EVAPORATE trial examined the effect of icosapent ethyl on plaque formation and was a mechanistic study for the REDUCE-IT trial.

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD
 Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.

Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD
Jeffrey Kroon presents his study on inflammatory mechanisms driving CV risk in patients with high Lp(a) levels and a potential new strategy to reduce atherogenesis in these patients.

Lp(a) meeting Jeffrey Kroon presents his study on inflammatory mechanisms driving CV risk in patients with high Lp(a) levels and a potential new strategy to reduce atherogenesis in these patients.

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD
Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

The mechanism of action of bempedoic acid

Feb. 2, 2020

Learn how bempedoic acid an ACL inhibtor works in reducing LDL-c

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD
Prof. Laufs points out the new emphasis in the ESC/EAS Dyslipidaemia Guidelines on high-risk patients, and shares evidence that forms the rationale for the treatment recommendations.

The new ESC/EAS Dyslipidaemia Guidelines focus on high-risk patients, and prof. Laufs shares evidence for the treatment recommendations. Test your knowledge

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD
Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema
Prof. Jukema explains the mechanism of epigenetics and how the BET inhibitor apabetalone can potentially impact CVD. In addition, he presents findings of first clinical studies with apabetalone.

Prof. Jukema explains the mechanism of epigenetics and how the BET inhibitor apabetalone can potentially impact CVD. In addition, he presents findings of first clinical studies with apabetalone.

Two choices of drugs that reduce CV risk in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD
Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD
Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits.

Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD
Prof. Montanya DMdiscusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trials, respectively.

Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.

Harmful effects of alcohol and smoking on arterial system in adolescents

3' education - Sep. 4, 2018 - Marietta Charakida, MD - London, UK
In a subanalysis of the ALSPAC study, higher alcohol consumption and smoking were associated with increased arterial stiffness in teenagers. The good news is that the harmful effects of smoking seem reversible.

In a subanalysis of the ALSPAC study, higher alcohol consumption and smoking were associated with increased arterial stiffness in teenagers. The good news is that the harmful effects of smoking seem reversible.

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018
Learn more about the mission of PACE-CME

Learn more about PACE-CME, our mission, our programmes and our cardiovascular educational services and resources

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France
Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.

Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.

Estimating CV risk and treatment benefit

Clinical updates in management of cardiovascular risk (4/4)

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

The role of lipids in CVD prevention: Lessons learned about statins

Clinical updates in management of cardiovascular risk (2/4)

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME
For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.

Clinical updates in management of cardiovascular risk For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.

Early intervention for lifetime CV risk reduction

Clinical updates in management of cardiovascular risk (1/4)

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME
CV risk factors that drive arterial disease in early life have a major impact on future CV risk. Communication about early lifestyle intervention to the public should be a major focus to reduce CV risk in later years.

Clinical updates in management of cardiovascular risk CV risk factors that drive arterial disease in early life have a major impact on future CV risk. Communication about early lifestyle intervention to the public should be a major focus to reduce CV risk in later years.

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands
Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.

Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA
Dr. Christopher Cannon explains the CV benefits of CETP inhibition in relation to non-HDL-c reduction

Dr. Christopher Cannon explains the CV benefits of CETP inhibition in relation to non-HDL-c reduction

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA
Dr. Samia Mora summarizes the challenges in lipid management with respect to testing and treatment.

Dr. Samia Mora summarizes the challenges in lipid management with respect to testing and treatment.

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

Analogous to LDL-c, the lower the better also seems true for inflammation

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA
A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but respons to treatment did.

AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but response to treatment did.

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

AHA 2017 - Anaheim, CA

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Inflammation expert opinions

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Inflammation Expert Opinions Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Inflammation expert opinions

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Inflammation Expert Opinions Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Inflammation expert opinions

5' education - Aug. 27, 2017
According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Inflammation Expert Opinions According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

Inflammation expert opinions

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.

Inflammation Expert Opinions Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.

Inflammation Expert Opinions Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

Inflammation expert opinions

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process.

Inflammation Expert Opinions Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process. Blocking this inflammation may be an additional treatment option beyond lipid lowering for CV risk reduction.

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon
Lina Badimon explica por qué el bloqueo de la inflamación puede representar un beneficio clínico significativo, debido al importante papel de la inflamación en la formación de la placa aterosclerótica.

Inflammation Expert Opinions Lina Badimon explica por qué el bloqueo de la inflamación puede representar un beneficio clínico significativo, debido al importante papel de la inflamación en la formación de la placa aterosclerótica. Los resultados de CANTOS pueden representar el inicio de una nueva era en la prevención cardiovascular.

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Inflammation expert opinions

10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation.

Inflammation Expert Opinions Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.

Imaging components of plaque not more informative than burden of plaque

ESC 2017 Barcelona

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia
Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when PCSK9 inhibitor evolocumab was added to intensive statin-treatment.

ESC 2017 Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when evolocumab was added to intensive statin-treatment.

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

Inflammation expert opinions

5' education - Aug. 28, 2017 - ESC 2017, Barcelona, Spain
Philippe Gabriel Steg réfléchit sur les résultats de l’étude CANTOS, qui soutient l’hypothèse que l’athérosclérose est une maladie chronique inflammatoire. Il considère que la validation de l’inflammation comme événement critique dans la prévention secondaire des évènements cardiovasculaires ouvre une nouvelle voie thérapeutique.

FRANCAIS Philippe Gabriel Steg réfléchit sur les résultats de l’étude CANTOS, qui soutient l’hypothèse que l’athérosclérose est une maladie chronique inflammatoire.

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Inflammation expert opinions

10' education - Aug. 28, 2017
Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.

Inflammation Expert Opinions Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.

LDL-c still reduced after 1 year with siRNA against PCSK9

ESC 2017 - Barcelona

3' education - Aug. 28, 2017
Safe and optimal treatment regimen identified for inclisiran, an siRNA against PCSK9, which is still effective after one year in the ORION-1 trial.

ESC 2017 Safe and optimal treatment regimen identified for inclisiran, an siRNA against PCSK9, which is still effective after one year in the ORION-1 trial.

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

ESC 2017 - Barcelona

3' education - Aug. 27, 2017
Paul Ridker shares what the results of the CANTOS trial mean to him as a clinician, in which lowering inflammation by inhibiting IL-1β with canakinumab reduced CV events in aggressively treated CV patients.

ESC 2017 Paul Ridker shares what the results of the CANTOS trial mean to him as a clinician. Lowering inflammation by inhibiting IL-1β with canakinumab reduced CV events in aggressively treated CV patients.

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA
Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works, it is safe, and you cannot force biology

PCSK9 Expert Opinions Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works – even lower is even better; it is safe, and you cannot force biology – it takes a long time to get atherosclerosis, so it will also take some time to get rid of it.

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA
Prof. Ulf Landmesser states that the results of both FOURIER and SPIRE fit into the concept that lowering LDL to very low levels results in a reduction in CV events

PCSK9 Expert Opinions Prof. Ulf Landmesser states that the results of both FOURIER and SPIRE fit into the concept that lowering LDL to very low levels results in a reduction in CV events

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA
According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

PCSK9 Expert Opinions According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA
Prof. Wolfgang Koenig argues that PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.

PCSK9 Expert Opinions Prof. Wolfgang Koenig describes the results of FOURIER and SPIRE. He expects that PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA
Prof. Richard Hobbs states that PCSK9 inhibition reduces endpoints that are important and expensive both for individuals and for health systems.

PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA
Prof. Gilles Lambert describes the development since the discovery in 2002 of PCSK9 until the results of outcome trials with a PCSK9 inhibitor in 2017.

PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA
Prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA
Dr. Paul M. Ridker states that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Kausik Ray describes the absence of a  J-shaped curve in the PCSK9 outcome trials,  meaning there is no apparent diminution of benefit to very low LDL.

PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA
Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2 and the implications for LDL-c lowering in high-CV risk individuals.

PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

3' education - Mar. 17, 2017
Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patient, as a consequence of development of antibodies against the drug.

ACC 2017 Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patients, as a consequence of development of antibodies against the drug.

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017
Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

Bisphosphonate as a potential new treatment for CV risk reduction

10' education - Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)
Bisphosphonates may impact calcification of the arterial intima media.

CSI Rome Guido Kranenberg studied the potential impact of bisphosphonate on calcification of the arterial intima media. He shares the findings of a systematic review and meta-analysis with Nicole Jaspers and they discuss which other studies might shed light on this relationship.

Inflammation, the immune system and atherosclerosis

10' education - July 7, 2015 - Amsterdam IAS

This discussion combines the mechanistic insights into the inflammatory component in atherogenesis of Jon Laman with the clinical perspective of Wolfgang Koenig. They discuss how inflammation reseach may change CV treatment approaches in the future.

Novel small molecule that inhibits PAI-1 in development to slow vascular aging

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Chicago, IL, USA
Novel small molecule that inhibits PAI-1 in development to slow vascular aging and prevented arteriosclerosis in mice, no toxicity signs in phase I study.

An investigational inhibitor of plasminogen activator inhibitor type 1 (PAI-1) prevented arteriosclerosis in mice and prolonged life in mice with a rapid aging phenotype. PAI-1 is a marker of cellular senescence, and the inhibitor is being developed to treat or slow down vascular aging.

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA
As a consequence of preventive therapies and changing risk factors, the pathofysiology of atherosclerosis, vulnerable plaque and ACS is changing.

Peter Libby considers how the pathophysiology of atherosclerosis and the mechanisms of ACS are changing, as a result of preventive therapies and a change in risk factors, toward superficial erosion.

Steps forward in lipid-lowering therapy

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA
Robert Giugliano summarises the recent evidence on lipid-lowering therapies beyond statins, in particular ezetimibe and PCSK9 inhibitors, with which further LDL-lowering can be achieved.

Robert Giugliano summarises the recent evidence on lipid-lowering therapies beyond statins, with which further LDL-lowering can be achieved.

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

3' education - Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##KEY_PHRASE##

ACC 2016 Data from the GAUSS-3 study show that muscle-related statin intolerance is a real problem and PCSK9 inhibition with evolocumab dramatically reduces LDL-c in these patients.

ACCELERATE: No reduction of major CV events with CETP inhibition

3' education - Apr. 7, 2016 - ACC, Chicago 2016 - Stephen J. Nicholls, MD, PhD
##KEY_PHRASE##

ACC 2016 Stephen Nicholls discusses the results of the ACCELERATE-study, in which the favourable effects of the CETP-inhibitor evacetrapib on cholesterol did not translate into any reduction in the primary endpoint.

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

Prof. Peter Libby (Boston, MA, USA) discusses how views on mechanisms of ACS have changed over time and how traditional thoughts on plaque composition and vulnerability are now challenged. He proposes a new mechanism of coronary thrombosis that may cause ACS.

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
CANTOS, canakinumab. A mechanism of action (MOA) video on the potential role of inflammation in atherothrombosis and residual cardiovascular risk

A mechanism of action video on the potential role of inflammation in atherothrombosis

Inflammation as target for therapy in atherothrombosis

Paul Ridker, MD - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##KEY_PHRASE##

Prof. Paul Ridker sets out how the hypothesised role for inflammation in atherosclerosis is now a pathway that can be targeted therapeutically. He consideres ongoing efforts to target the inflammatory response.

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby
##KEY_PHRASE##

ISA 2015 Prof. Peter Libby recapitulates evolving insights into the mechanism of acute coronary syndromes, and how we may be shifting from a predominance of plaque ruptures towards superficial erosion as the cause of ACS.

CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Yanan Wang
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Yanan Wang showed in a humanised animal model, the CETP-inhibitor anacetrapib reduced atherosclerosis development, by lowering non-HDL-c levels, via increased uptake in the liver. In addition, anacetrapib reduces plasma PCSK9 levels.

Cardiovascular Inflammation and Immunity in Atherosclerosis:

Clinical Perspectives

10' education - June 7, 2015 - Amsterdam

Prof Peter Libby, Boston, USA, discusses the implications of recent insights in inflammation in atherosclerosis with Göran Hansson, Stephen Nicholls and Paul Ridker.

Statin-loaded HDL nanoparticles

10' education - Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden

Raphael Duivenvoorden, Amsterdam, describes an innovative nanotechnique to reduce the risk of a recurrent myocard infarct, in which inflammation is a key factor.